This is just a tiny glimpse of the data available to CivicScience clients. Discover more data. CivicScience has data on over ...

If you're a doctor, you probably had some insight into what an incredibly popular phenomenon GLP-1 drugs would be before ... commercial real estate. In CRE, I think I can discern what's true ...

They're known to aid in blood sugar control and, now, weight loss — but, according to a sweeping new study, the popular GLP-1 ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

LifeVantage (LFVN) announced the completion of an international in vitro cell study that investigated the effects of its international ...

Realistically, there’s a good chance your patients are using them to get GLP-1 agonists. And sometimes Ro’s practice will resort to using compounding pharmacies too, only if all other options ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

As Stacey Leasca reports for “Food & Wine,” research from Cornell University found that households with at least one GLP-1 user are significantly reducing their grocery spending. The paper ...

However, a new class of medications, GLP-1 agonists, originally designed for diabetes and obesity management, shows promise as a revolutionary tool in addiction treatment. GLP-1, or glucagon-like ...

It’s a synthetic version of the hormone GLP-1, which helps regulate our metabolism and hunger. Semaglutide and other newer GLP-1 medications have proven to be far more effective at treating ...